{"entity":{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","aka":[],"tldr":"Recursion is an AI-first biotech (merged with Exscientia in 2024) with a clinical oncology pipeline that includes an RBM39 degrader and a MEK inhibitor for familial adenomatous polyposis.","summary":"Recursion Pharmaceuticals, based in Salt Lake City and listed as RXRX, is an AI-first biotechnology company that merged with Exscientia in 2024, with a clinical oncology pipeline including an RBM39 degrader and a MEK inhibitor for familial adenomatous polyposis. Its programmes include REC-1245, the RBM39 degrader in phase 1/2, REC-4881, a MEK1/2 inhibitor in phase 2 for FAP with FDA registrational discussions, and candidates against LSD1, CDK7, PI3K-alpha H1047R, MALT1 and ENPP1, and it reported revenue shortfalls alongside pipeline progress in the first quarter of 2026. OnCo links it to colorectal cancer, AI-driven discovery and protein degradation, the MAPK and cGAS-STING pathways and the idea of a virtual cancer cell. Whether AI-discovered candidates succeed in the clinic at a higher rate than conventional ones is the question the company exists to test.","asOf":"2026-09-04","links":[{"label":"Q1 2026 update","url":"https://ir.recursion.com/news-releases/news-release-details/recursion-reports-first-quarter-financial-results-and-provides"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["ai-computation","drug-discovery"],"technologies":["ai-drug-design","protac-degrader"],"targets":["pik3ca"],"drugs":[],"companies":[],"institutions":[],"pathways":["ras-mapk","cgas-sting"],"terms":[],"trials":["nct05985655","nct06678659"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Salt Lake City, UT","country":"US","companyType":"ai-software","website":"https://www.recursion.com","ticker":"RXRX","investors":[],"funding":[]},"route":"/companies/recursion/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"boltz","kind":"technology","name":"Boltz-1 / Boltz-2 (MIT, open)","route":"/technologies/boltz/"},{"id":"phenom-2","kind":"technology","name":"Phenom-2 and Recursion OS","route":"/technologies/phenom-2/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"target":[{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"}],"pathway":[{"id":"cgas-sting","kind":"pathway","name":"cGAS-STING innate sensing","route":"/pathways/cgas-sting/"},{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/"}],"trial":[{"id":"nct06678659","kind":"trial","name":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","route":"/trials/nct06678659/"},{"id":"nct05985655","kind":"trial","name":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","route":"/trials/nct05985655/"}],"bottleneck":[{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/"},{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}],"idea":[{"id":"idea-bio1-virtual-cell-perturbation","kind":"idea","name":"A virtual cancer cell that predicts what a drug will do before you test it","route":"/ideas/idea-bio1-virtual-cell-perturbation/"},{"id":"idea-moon-self-driving-cancer-labs","kind":"idea","name":"Self-driving laboratories that run the cancer biology hypothesis loop autonomously","route":"/ideas/idea-moon-self-driving-cancer-labs/"}],"company":[{"id":"exscientia","kind":"company","name":"Exscientia","route":"/companies/exscientia/"}],"roadmap":[{"id":"ai-oncology-roadmap","kind":"roadmap","name":"AI in oncology roadmap: pattern readers → foundation models → agents in the workflow","route":"/roadmaps/ai-oncology-roadmap/"},{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/"}]}}